Pharma Focus Asia

Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration

Wednesday, July 19, 2017

Zymeworks Inc., a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation bispecific and multifunctional biotherapeutics, initially focused on the treatment of cancer, and Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) today announced the successful achievement of a research milestone for an immuno-oncology bispecific antibody therapeutic candidate in their collaboration. In conjunction with this milestone achievement, Zymeworks is to receive a milestone payment of one million dollars from Daiichi Sankyo.

Under the terms of their existing agreement signed on September 26, 2016, Zymeworks granted Daiichi Sankyo a license to Zymeworks’ Azymetric™ and EFECT™ platforms to develop a bispecific antibody therapeutic for which Zymeworks is eligible to receive preclinical, clinical and commercial milestone payments, as well as up to double-digit tiered royalties on global product sales. Additionally, Zymeworks obtained a license to certain immuno-oncology antibodies from Daiichi Sankyo, with the right to research, develop and commercialize multiple bispecific products globally in exchange for royalties on global product sales.

“We are very excited by the rapid progress we have made in our collaboration with Daiichi Sankyo, which further demonstrates the versatility and biophysical robustness of the Azymetric™ platform, and we continue to work closely with Daiichi Sankyo towards advancing this potential immuno-oncology therapeutic towards the clinic,” said Dr. Ali Tehrani, President and CEO of Zymeworks. “In parallel, we are continuing to develop and advance other novel immunomodulatory bispecific antibodies incorporating the immuno-oncology antibodies that were in-licensed from Daiichi Sankyo to expand Zymeworks’ pipeline of therapeutic candidates.”

“We are pleased that we have been able to reach this research milestone for the development of this bispecific antibody with Zymeworks,” said Toshinori Agatsuma, Ph.D., Vice President, Biologics & Immuno-Oncology Laboratories at Daiichi Sankyo. “We look forward to continued success with this collaboration to help strengthen our bispecific antibody development capabilities in order to help change the standard of care for patients with cancer.”

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024